Skip to main content

COVID 19 Updates from RheumNow

RheumNow Podcast – Driving in Pain (8.20.2021)

Dr. Jack Cush reviews the news, journal articles and more from this past week on RheumNow.com.

Sustained Effectiveness of mRNA Vaccines Against COVID-19 Hospitalizations

MMWR

The CDC has reported that mRNA vaccine effectiveness against COVID-19–associated hospitalizations was sustained over 24 weeks; but there is evidence of waning protection amongst the immunosuppressed.

HHS, FDA & CDC Joint Recommendation on COVID Booster

FDA

Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people.

Booster Shots for Rheumatology Patients on Immunosuppressive Medications

ACR Press Release

ATLANTA – The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices today recommended that rheumatology patients being actively treated with high-dose corticosteroids, alkylating agents, antimetabolites, tumor-necrosis factor (TNF) blockers, and other bio

RheumNow Podcast – Booster Shots for COVID (8.13.2021)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Anakinra's Effects on COVID-19 Outcomes

Sporadic reports of anakinra use in COVID-19 infection has hinted is potential; now a metanalysis shows that the use of anakinra may reduce the mortality risk in patients admitted to hospital with moderate to severe COVID-19 pneumonia, especially highly elevated ferritin and C-reactive protein (C

COVID Vaccine Booster Effective for Transplant Recipients in Small Trial

MedPage Today

For organ transplant recipients, a third dose of Moderna's COVID-19 vaccine more than tripled the proportion with a sufficient antibody response, a randomized trial showed.

Rare Risk of Serious Adverse Events After COVID Vaccination

CDC/MMWR

The CDC had reported the Advisory Committee on Immunization Practices (ACIP) study of rare serious adverse events after COVID-19 vaccination and assert that the excessive morbidity and mortality from COVID-19 (and the protection afforded by vaccination) far exceeds the risk of rare safety signals

RheumNow Podcast – Psoriatic Arthritis Without Psoriasis (7.30.2021)

Dr Jack Cush reviews rheumatology and COVID news from the past week on RheumNow.com.

CDC Reverses Stance on Masks

Today the Centers for Disease Control and Prevention (CDC) said that masks should be used by those vaccinated against the coronavirus in public indoor spaces in parts of the country where the virus is surging.

DMARD Effects on COVID-19 Outcomes

Sparks and colleagues have published data from the Global Rheumatology Alliance noting that among rheumatoid arthritis (RA) patients afflicted with COVID-19 infection, there was little influence of their baseline biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs)

Canakinumab Fails to Improve COVID-19 Survival

JAMA has published the findings of trial wherein the anti–interleukin-1β antibody canakinumab (CAN) failed to improve survival in patients hospitalized with severe COVID-19.

Social

Analysis of existing #COVID data - as of 7/15/21, 114.9 million adults infected with COVID-19 in US. Overall population immunity (Infx+vax) is 62%, highest in adults >65yrs (77.2%); lowest in children <12 yrs (17.9%) https://t.co/EYiBUaQBLY

Dr. John Cush @RheumNow ( View Tweet )

1 week ago
ICYMI: American College of OBs & GYNS and the Society for Maternal-Fetal Medicine both enthusiastically endorse COVID Vaccination of pregnant women, given the delta variant, low vax rates in Preg women and poor COVID outcomes in preg. https://t.co/AmP5eOEgr3 #RheumNow https://t.co/wXeT1KDCrJ
Dr. John Cush @RheumNow ( View Tweet )
1 week 1 day ago
In case you missed it… Breakthrough COVID infection. Breakthrough brilliance in a KOL A must read from Len Calabrese https://t.co/2Ljzau5nBG #RheumNow

Dr. John Cush @RheumNow ( View Tweet )

1 week 1 day ago
ICYMI: Probenecid, an OAT3 inhibitor, has inhibitory effects on RNA viruses (influenza, RSV) & decreases ACE2 expression. May have utility in COVID-19 as it was shown to inhibit SARS-CoV-2 replication in animal models https://t.co/MClSjpqpSa #RheumNow

Dr. John Cush @RheumNow ( View Tweet )

1 week 2 days ago
Another non stellar result for remdesivir Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): P3, randomised, controlled, open-label trial ⁦@TheLancetInfDis⁩ https://t.co/kNSNj9RM4K

Dr Philip Robinson @philipcrobinson ( View Tweet )

1 week 3 days ago
American College of OBs & GYNS and the Society for Maternal-Fetal Medicine both enthusiastically endorse COVID Vaccination of pregnant women, given the delta variant, low vax rates in Preg women and poor COVID outcomes in preg. https://t.co/AmP5eOEgr3

Dr. John Cush @RheumNow ( View Tweet )

1 week 4 days ago
Study of 265 students w/ a positive COVID-19 test looked at 378 close contacts. Infx rates w both persons masked -7.7%, but when unmasked-32.4% (aORs = 4.9;) https://t.co/fYdH33JbWR

Dr. John Cush @RheumNow ( View Tweet )

1 week 5 days ago
Baricitinib & Tofacitinib are effective in COVID-19 pts. These drugs are expensive; baricitinib is $44/tablet, but much lower for generics worldwide. 14 day course of TOFA would be >$1,400 in the US (but $600 in France, $25 in India) https://t.co/r2cn1H2z8i

Dr. John Cush @RheumNow ( View Tweet )

1 week 6 days ago
MMWR reports that during the COVID Delta variant era, Vaccination against COVID-19: - Reduces risk of COVID-19 infection 5X - Reduces risk of COVID-19 Hospitalization >10X - Reduces risk of COVID-19 DEATH 10X https://t.co/rMRY84xX5F

Dr. John Cush @RheumNow ( View Tweet )

2 weeks ago
Probenecid, an OAT3 inhibitor, has inhibitory effects on RNA viruses (influenza, RSV) & decreases ACE2 expression. May have utility in COVID-19 as it was shown to inhibit SARS-CoV-2 replication in animal models https://t.co/MClSjpqpSa

Dr. John Cush @RheumNow ( View Tweet )

2 weeks ago
×